The biotechnological development of monoclonal antibodies and their immunotherapeutic use in oncology have grown exponentially in the last decade, becoming the first-line therapy for some types of cancer. Their mechanism of action is based on the ability to regulate the immune system or by interacting with targets that are either overexpressed in tumor cells, released into the extracellular milieu or involved in processes that favor tumor growth. In addition, the intrinsic characteristics of each subclass of antibodies provide specific effector functions against the tumor by activating antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, among other mechanisms. The rational design and engineering of monoclonal antibodies have improved their pharmacokinetic and pharmacodynamic features, thus optimizing the therapeutic regimens administered to cancer patients and improving their clinical outcomes. The selection of the immunoglobulin G subclass, modifications to its crystallizable region (Fc), and conjugation of radioactive substances or antineoplastic drugs may all improve the antitumor effects of therapeutic antibodies. This review aims to provide insights into the immunological and pharmacological aspects of therapeutic antibodies used in oncology, with a rational approach at molecular modifications that can be introduced into these biological tools, improving their efficacy in the treatment of cancer.

MicroRNAs (miRNAs) are small non-coding RNAs that participate as powerful genetic regulators. MiRNAs can interfere with cellular processes by interacting with a broad spectrum of target genes under physiological and pathological states, including cancer development and progression. Major histocompatibility complex major histocompatibility complex class I-related chain A (MICA) belongs to a family of proteins that bind the natural-killer group 2, member D (NKG2D) receptor on Natural Killer cells and other cytotoxic lymphocytes. MICA plays a crucial role in the host’s innate immune response to several disease settings, including cancer. MICA harbors various single nucleotide polymorphisms (SNPs) located in its 3′-untranslated region (3′UTR), a characteristic that increases the complexity of MICA regulation, favoring its post-transcriptional modulation by miRNAs under physiological and pathological conditions. Here, we conducted an in-depth analysis of MICA 3′UTR sequences according to each MICA allele described to date using NCBI database. We also systematically evaluated interactions between miRNAs and their putative targets on MICA 3′UTR containing SNPs using in silico analysis. Our in silico results showed that MICA SNPs rs9266829, rs 1880, and rs9266825, located in the target sequence of miRNAs hsa-miR-106a-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-20b-5p, hsa-miR-93, hsa-miR-1207.5p, and hsa-miR-711 could modify the binding free energy between −8.62 and −18.14 kcal/mol, which may affect the regulation of MICA expression. We believe that our results may provide a starting point for further exploration of miRNA regulatory effects depending on MICA allelic variability; they may also be a guide to conduct miRNA in silico analysis for other highly polymorphic genes.

• Three label-free methods and ELISA were compared to assess scFv–MICA binding affinity for therapeutic candidate selection. • Surface plasmon resonance (SPR) yielded the most precise and discriminative affinity measurements of the scFv variants. • The wild-type scFv showed superior binding, stability, and functionality compared to the Beta mutant. • Combined biophysical, in silico, and cellular data support the wild-type scFv as a promising therapeutic candidate.

Major histocompatibility complex class I chain-related gene A (MICA) is a non-classical MHC-I molecule essential for immune surveillance, yet its intracellular maturation remains poorly understood. We show that MICA is predominantly retained intracellularly in melanoma cells and colocalizes with the endoplasmic reticulum chaperone calreticulin (CRT). Notably, MICA also colocalizes with CRT in healthy skin. Immunoprecipitation assays reveal that CRT preferentially associates with a low-molecular-weight form of MICA. Recombinant protein assays and in silico analyses support direct interaction between CRT and non-glycosylated MICA, but not with fully glycosylated eukaryotic MICA. These findings identify CRT-dependent retention of MICA as a physiological checkpoint that may be dysregulated in melanoma to promote immune evasion.

Background: MICA is a stress-induced ligand for the activating receptor NKG2D and plays a central role in immune recognition and elimination of tumor cells. Tumor-derived soluble MICA (sMICA) and its allelic diversity impair immune responses by disrupting NKG2D function and promoting immune evasion, highlighting the need for antibody-based strategies targeting the MICA/NKG2D axis. Methods: We generated a fully human IgG1 monoclonal antibody targeting the α1 domain of MICA using phage display and rational epitope design focused on a conserved, low-polymorphic region. We characterized its binding specificity and affinity for MICA, competition with NKG2D, and its ability to trigger immune effector functions, including antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and activation of the classical complement pathway. Results: The antibody displayed high affinity for recombinant MICA (app K _d ≈ 20 nM) and effectively competed with NKG2D (K _i ≈ 15 nM). It recognized multiple MICA alleles expressed in human gastric and leukemia cell lines, confirming broad allelic coverage. Functional assays showed that the antibody mediated strong CDC, ADCC by NK cells and promoted ADCP of MICA-expressing cells. Conclusion: By combining high-affinity recognition of broad MICA alleles and robust activation of immune effector functions, this fully human anti-MICA α1 antibody offers a novel strategy to modulate the MICA/NKG2D axis and activate Fc-mediated immune effector functions against MICA-expressing tumor cells. Its dual mechanism of action supports its development as a standalone or combinatorial agent with immune checkpoint inhibitors in MICA-expressing tumors.